Systemic sclerosis is a generalized disorder characterized by fibrosis
and microvascular injury in affected organs. Despite being recognized
nearly 250 years ago, knowledge regarding pathogenesis remains Limite
d, and treatment remains directed at symptomatic improvement. Early re
cognition of systemic sclerosis, however, is important in order to mon
itor for specific disease complications (i.e., fibrosing alveolitis, s
cleroderma renal crisis) as well as initiate manifestation specific th
erapies that improve quality of life.